The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
British Journal of Dermatologyl
If you experienced complications after a missed muscle injection, you might file a lawsuit against the healthcare provider who gave you the injection
These peptides have shown significant promise in promoting tendon and ligament healing, reducing inflammation, and enhancing muscle repair
I. Schelleret al., Thymosin 4 is essential for thrombus formation by controlling the G-actin/F-actin equilibrium in platelets, Ferrata Storti Foundation (Haematologica), Aug. 2021. doi: 10.3324/haematol.2021.278537
Increasing flexibility and mobility post-injury
